Q3 results from the 10 largest pharmaceutical companies: Pfizer, Novaral, Roche...

Pharmaceutical Network November 2nd, the top 10 MNC pharmaceutical companies Q3 financial results: Pfizer, Novarma, Roche, Lilly, Novarma ... Starting in October, the global pharmaceutical giants have released their 2020 Q3 results! So far, according to incomplete statistics, 10 MNC pharmaceutical companies have published Q3 "report card": Sanofi, Lilly, Gilead, GSK, Mercadon, Novarma, Pfizer, Yan Jian, Roche, Johnson and Johnson.
this paper will be combed from the pharmaceutical company's revenue situation, the performance of fist products and 2021 development forecast, hoping that these "report card" to help pharmaceutical people better understand the global pharmaceutical industry dynamics.
(the following pharmaceutical company earnings will be arranged by the time of the release of the financial results) 1, Sanofi China's performance declined significantly, Dupixent growth was strong October 29, Sanofi announced 2020Q3 results, net sales revenue of 9.479 billion euros, down 0.2%;
Sanofi Q3 professional care sales were EUR 2,753 million, up 23.8% YoY, generic drug sales were EUR 3,608 million, down 6.4% YoY, vaccine sales were EUR 2,077 million, up 13.6% YoY, and consumer health sales were EUR 1,041 million, down 1.1% YoY.
by region, Sanofi Q3's sales from the United States amounted to EUR 3,974 million, or 41.9% of total sales, while sales from Europe amounted to EUR 2,272 million, or 24% of total sales, and sales from other regions amounted to EUR 3,233 million, or 34.1% of total sales.
results, Sanofi's third-quarter results were driven largely by strong demand for the monoclonal antibody drug Dupixent, which targets IL-4R, and flu vaccines.
, which generated sales of 2.552 billion euros (-83.5 percent) in the first three quarters of the year, is a star product of Sanofi's revenue stream.
In addition, Sanofi referred to "China" 28 times in its Q3 earnings press release and noted that its decline in China was mainly affected by volume purchases, noting in particular that Pllavix Q3 had sales of only 205 million euros (-39.9%) and Clopidogrel Q3 had revenues of 72 million euros (-64.1%) in China.
2, Lilly China's strong growth, Daboshu exceeded $200 million on October 29, Lilly released its 2020 Q3 results, third quarter global revenue increased 5% year-on-year to $5.74 billion.
The top three sales were the type 2 diabetes drug Eda (Doraglutide), which exceeded $1 billion in Q3 sales, Utrex insulin, which sold $656.9 million, up 1% year-on-year, and Libita, which is widely used for multiple cancers, with sales of $578 million, up 14% year-on-year.
In China, Lilly's third-quarter revenue rose 10 percent year-on-year to $289 million, compared with a 15 percent increase in the first three quarters to $796 million, delivering strong growth in business volume, offsetting lower prices for heavy drugs such as PD-1 inhibitors Dabershu (Syndicate Monoanti) and Libitai.
is an important source of revenue growth for Lilly in China, and in August, Lilly gained exclusive rights to develop and commercialize Dabershu outside China.
Q3 sales reached $84.4 million, up 81% year-on-year, and exceeded $206 million in the first three quarters, up 96.6% year-on-year.
addition, Lilly Q3 invested a total of $125 million in the development of new coronary pneumonia treatment drugs and submitted applications in the United States for emergency use authorization for patients with high-risk mild to moderate new coronary pneumonia.
2020, Lilly has 48 applications for 14 products approved, including 27 clinical applications and 13 supplementary applications.
3, Gilead Q3 performance growth is strong, Redsiway sales of $785 million on October 28, Gilead announced 2020Q3 results, product revenue of $6.493 billion, up 18% YoY, the first three quarters of cumulative product revenue of $17,027 million, up 4% YoY.
sales of Veklury, a COVID-19 product, reached $873 million in the third quarter, including $785 million in the U.S. and $60 million in Europe.
Redsivi is currently approved/licensed in 50 countries around the world, and the FDA officially approved Redsyves on October 21 for the treatment of COVID-19 inpatients, with the European Union conditionly approving the drug on July 3.
because of the agreement with HHS in the United States, Redsiway 2020Q3 sales are mostly from the U.S. market, Gilead expects the drug's sales in 2020Q4 will be mainly contributed by outside the U.S.
European Commission signed a joint procurement agreement with Gilead on October 8.
4, GlaxoSmithKline's revenues fell, the new crown vaccine is about to enter the third phase of October 28, GlaxoSmithKline announced 2020 Q3 results: Q3 sales of 8.646 billion pounds, in real exchange rate (AER) down 8% Year-on-Year, total operating profit of 1.858 billion pounds, down 13% YoY in real exchange rates.
of these, sales in the pharmaceutical sector were ￡4.2bn, down 7 per cent year-on-year in real terms, vaccine sales were ￡2bn, down 12 per cent in real terms, and consumer health sector sales were ￡2.4bn, down 4 per cent year-on-year in real terms.
new crown vaccine, GlaxoSmithKline's phase III trial of the new crown vaccine, developed in partnership with Sanofi (SNY.US), is expected to begin in December 2020.
agreement with the United States, the European Union, the United Kingdom and Canada to supply Sanofi-GlaxoSmithKline's new crown vaccine.
, phase III trials of VIR-7831, a candidate for the new coronavirus monoclonal antibody (mAb), are under way and are expected to produce preliminary results by the end of 2020.
5, Merca East China's strong performance, K drug sales of more than 10 billion U.S. dollars on October 27, Merca East announced 2020Q3 results, revenue of 12.551 billion U.S. dollars, up 1% YoY, pharmaceutical business revenue of 11.320 billion U.S. dollars, up 2% YoY.
revenue for the first three quarters of 2020 was $35.479 billion, up 1% year-on-year.
, Merca East 2020Q3 China's revenue was $990 million, up 10% year-on-year.
revenue for the first three quarters of 2020 reached $2,646 million, surpassing Japan as the world's third-largest market outside the United States and the European Union.
from a product perspective, Mercedon Keytruda's sales in 2020Q3 were $3,715 million, up 21%, and cumulative revenue for the first three quarters had reached $10,387 million, up 31%.
addition, Lynparza (Olapali) and Lenvima (Levatini), which are deeply tied to AstraZeneta, achieved growth of 58% and 29% respectively in 2020Q3.
vaccine product Gardasil 9 has gradually recovered from the impact of COVID-19, with sales of $1,187 million in 2020Q3, down 10% YoY, and cumulative revenue of $2,941 million in the first three quarters of 2020, down 2% YoY.
In the development of COVID-19 drugs and vaccines, Molenupiravir (MK-4482), an oral antiviral candidate developed by Mercadon in partnership with Ridgeback Bio, has initiated two key Phase II/III clinical studies, one of which plans to recruit 1,450 outpatient COVID-19 adult patients and the other to recruit 1,300 hospitalized COVID-19 adult patients.
candidate vaccine V591 has entered the phase I clinical stage, V590 is about to enter the phase I clinical.
6, Novart Q3 strong results, revenue and profit double October 27, Novart released the first three quarters of 2020 results, net sales revenue of $35,889 million, up 4% YoY, core operating profit of $11.915 billion, up 16% YoY.
Q3's net sales revenue was $12,259 million, of which China's revenue was $667 million, or 13 percent, or 4.468 billion yuan, driven by double-digit growth rates in Cosentyx and Entresto.
specific products, Novart had sales of more than $1 billion in eight products in the first three quarters of 2020.
, Cosentyx had sales of $2,886 million, Gilenya of $2,243 million (-7%) and Entresto of $1,781 million, or 48%.
Afinitor and Exjade saw patent breaks in 2020, with a flood of generics flooding the market and sales plummeting, with Afinitor sales down 35 per cent to $262m and Exjade down 36 per cent to $162m.
Despite the impact of COVID-19 on the healthcare system, Novart will continue to perform solidly, with double-digit growth in core operating income and expanding margins," said Vas Narasimhan, Chief Executive Officer of Novarco.
our key growth drivers and product launches performed well.
our underlying business enables us to improve our full-year 2020 core operating income guidance.
"7, Pfizer's strong performance fell 18 percent, the new crown vaccine progress is good October 27, Pfizer announced 2020Q3 results, total revenue of $12.131 billion, down 4 percent year-on-year.
, biopharmaceutical revenue was $10.215 billion, up 4% year-on-year, while revenue from pro-pharma was $1,916 million, down 18% year-on-year.
revenue for the first three quarters of 2020 was $35,961 million, down 7 percent from a year earlier.
results showed an 18 per cent decline in the company's 2020Q3 results, mainly due to generics from Lyrica in the US and Cerebrex in Japan, as well as purchases of Lipitor and Norvasc in China.
same time, Pfizer's mRNA vaccine BNT162, developed in cooperation with BioNTech, has been added to more than 42,000 subjects in 150 clinical trial facilities in six countries, and as of October 26, about 36,000 subjects had been vaccinated with the second dose.
Pfizer has also expanded its planned group from 30,000 to 44,000.
Pfizer also said that assuming positive data, the new vaccine will be submitted in the U.S. in the third week of November.
addition, Pfizer's antiviral candidates have started phase IB clinical studies in September and plan to launch critical Phase II/III clinical trials later in 2020/early 2021.
8, Yanjian's revenue profit fell, the new drug development ended October 22, Biogen released the 2020 Q3 financial results, the third quarter of total revenue of $3.376 billion, year-on-year -6%, net profit of $702 million, up -54% year-on-year.
Among them, multiple sclerosis (MS) drug Ocrevus sales were $2,257 million, up -4% YoY, spinal muscular dystrophy (SMA) drug Spinraza sales were $495 million, down -10% YoY, and biosimilar revenue was up 13% year-on-year to $208 million.
addition to its poor performance, Yan Jian also announced that it had stopped the follow-up development of its MS drug Opicinumab.
, He also advised investors to continue to focus on their new partnership with Denali Therapeutics, which could focus on Parkinson's syndrome in 2021.
, Roche Pharmaceuticals fell significantly, the diagnosis rose on October 18, Roche released 2020 Q3 results: the Group's global revenue of 14.698 billion Swiss francs ($16.102 billion), up -5.8% YoY.
of which pharmaceutical revenue was 11.115 billion Swiss francs, up -10.1% YoY, accounting for 76% of total revenue, and diagnostic revenue was 3.583 billion Swiss francs, up 10.9% YoY, accounting for 24% of total revenue.
Pharmaceuticals declined overall: revenue in the U.S. was 5,925 million Swiss francs, up 11.1 percent year-on-year; in Europe, revenue was 2,078 million Swiss francs, the same as last year; in Japan, revenue was 894 million Swiss francs, up 17.4 percent year-on-year; and in international markets, including China, revenue was 2,218 million Swiss francs, up 12.1 percent year-on-year.
Roche's decline was mainly due to the global spread of COVID-19, which led to a significant decline in outpatient and inpatient patients, and the decline in competitive pressure from generic drugs caused by the "Three Aces" (Beva Beva Bead Monoanti, Lytoxi Monoanti, QutoJu Monoanti).
but the multiple sclerosis drug Ocrevus, the breast cancer drug Perjeta, PD-L1 product Tecentriq and hemophilia new drug Hemlibra showed a stronger driving force for new life.
diagnostics business as a whole: Central Laboratories and POC Diagnostics revenue of 1.847 billion Swiss francs, revenue -7.8% YoY, is the most serious decline in the diagnostics sector, but compared to -15% in the first half of the year, is already up; Swiss francs, with revenues of 97% YoY, was the strongest driver of growth in Roche's diagnostics business Q3, while diabetes management revenue was 429 million Swiss francs, up 1.8% YoY, and organizational diagnostics revenue was 287 million Swiss francs, up 5.5% YoY.
10, Johnson and Johnson's overall results rose slightly, China's strong performance in mid-October, Johnson and Johnson released 2020 Q3 financial results: Johnson and Johnson global revenue reached $21 billion, up 1.7% year-on-year.
, global drug sales were 114